A detailed history of Dc Funds, LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Dc Funds, LP holds 630,000 shares of TCRX stock, worth $1.85 Million. This represents 47.72% of its overall portfolio holdings.

Number of Shares
630,000
Previous 630,000 -0.0%
Holding current value
$1.85 Million
Previous $3.69 Million 14.87%
% of portfolio
47.72%
Previous 50.4%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

BUY
$6.17 - $13.48 $3.89 Million - $8.49 Million
630,000 New
630,000 $5.25 Million

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $55.5M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Dc Funds, LP Portfolio

Follow Dc Funds, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dc Funds, LP, based on Form 13F filings with the SEC.

News

Stay updated on Dc Funds, LP with notifications on news.